Prostate Cancer

Rouprêt M, Hupertan V, Catto JW, Yates DR, Rehman I, Proctor LM, Phillips J, Meuth M, Cussenot O, Hamdy FC.

Promoter hypermethylation in circulating blood cells identifies prostate cancer progression.

Int J Cancer. 2008;122(4):952-6.

Woodson K, O'Reilly KJ, Hanson JC, Nelson D, Walk EL, Tangrea JA.

The usefulness of the detection of GSTP1 methylation in urine as a biomarker in the diagnosis of prostate cancer.

J Urol. 2008;179(2):508-11;

Henrique R, Ribeiro FR, Fonseca D, Hoque MO, Carvalho AL, Costa VL, Pinto M, Oliveira J, Teixeira MR, Sidransky D, Jerónimo C.

High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients.

Clin Cancer Res. 2007;13(20):6122-9.

Meiers I, Shanks JH, Bostwick DG.

Glutathione S-transferase pi (GSTP1) hypermethylation in prostate cancer: review 2007.

Pathology. 2007;39(3):299-304. Review.

Rouprêt M, Hupertan V, Yates DR, Catto JW, Rehman I, Meuth M, Ricci S, Lacave R, Cancel-Tassin G, de la Taille A, Rozet F, Cathelineau X, Vallancien G, Hamdy FC, Cussenot O.

Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage.

Clin Cancer Res. 2007;13(6):1720-5.

Additional Publications

Rogers CG, Gonzalgo ML, Yan G, Bastian PJ, Chan DY, Nelson WG, Pavlovich CP.

High concordance of gene methylation in post-digital rectal examination and post-biopsy urine samples for prostate cancer detection.

J Urol. 2006;176(5):2280-4.

Perry AS, Foley R, Woodson K, Lawler M.
The emerging roles of DNA methylation in the clinical management of prostate cancer.
Endocr Relat Cancer. 2006;13(2):357-77.

Henrique R, Jeronimo C, Teixeira MR, Hoque MO, Carvalho AL, Pais I, Ribeiro FR, Oliveira J, Lopes C, Sidransky D.
Epigenetic heterogeneity of high-grade prostatic intraepithelial neoplasia: clues for clonal progression in prostate carcinogenesis.
Mol Cancer Res. 2006;4(1):1-8.

Hoque MO, Topaloglu O, Begum S, Henrique R, Rosenbaum E, Van Criekinge W, Westra WH, Sidransky D
Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects.
J Clin Oncol. 2005;23(27):6569-75.

Jeronimo C, Henrique R, Hoque MO, Mambo E, Ribeiro FR, Varzim G, Oliveira J, Teixeira MR, Lopes C, Sidransky D.
A quantitative promoter methylation profile of prostate cancer.
Clin Cancer Res. 2004;10(24):8472-8.

Harden SV, Sanderson H, Goodman SN. Partin, AA, Walsh PC, Epstein JI, Sidransky D.
Quantitative GST-Pi methylation improves the detection of prostate adenocarcinoma in sextant biopsies.
J Nat Cancer Inst 2003;95(21):1634-7.


Vanaja DK, Ballman KV, Morlan BW, Cheville JC, Neumann RM, Lieber MM, Tindall DJ, Young CY.
PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer.
Clin Cancer Res. 2006;12(4):1128-36.

Collard RL, Harya NS, Monzon FA, Maier CE, O'Keefe DS.
Methylation of the ASC gene promoter is associated with aggressive prostate cancer.
Prostate. 2006;66(7):687-95.

Rosenbaum E, Hoque MO, Cohen Y, Zahurak M, Eisenberger MA, Epstein JI, Partin AW, Sidransky D.
Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
Clin Cancer Res. 2005;11(23):8321-5.

Enokida H, Shiina H, Urakami S, Igawa M, Ogishima T, Li LC, Kawahara M, Nakagawa M, Kane CJ, Carroll PR, Dahiya R.
Multigene methylation analysis for detection and staging of prostate cancer.
Clin Cancer Res. 2005;11(18):6582-8.

Bastian PJ, Ellinger J, Wellmann A, Wernert N, Heukamp LC, Muller SC, von Ruecker A.
Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci.
Clin Cancer Res. 2005;11(11):4097-106.

Bastian PJ, Palapattu GS, Lin X, Yegnasubramanian S, Mangold LA, Trock B, Eisenberger MA, Partin AW, Nelson WG.
Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy.
Clin Cancer Res. 2005;11(11):4037-43.

Henrique R, Jeronimo C, Hoque MO, Nomoto S, Carvalho AL, Costa VL, Oliveira J, Teixeira MR, Lopes C, Sidransky D.
MT1G hypermethylation is associated with higher tumor stage in prostate cancer.
Cancer Epidemiol Biomarkers Prev. 2005;14(5):1274-8.

Lodygin D, Epanchintsev A, Menssen A, Diebold J, Hermeking H.
Functional epigenomics identifies genes frequently silenced in prostate cancer.
Cancer Res. 2005;65(10):4218-27.

Henrique R, Jeronimo C, Hoque MO, Carvalho AL, Oliveira J, Teixeira MR, Lopes C, Sidransky D.
Frequent 14-3-3 sigma promoter methylation in benign and malignant prostate lesions.
DNA Cell Biol. 2005;24(4):264-9.

Li LC, Carroll PR, Dahiya R.
Epigenetic changes in prostate cancer: implication for diagnosis and treatment.
J Natl Cancer Inst. 2005;97(2):103-15.

Bastian PJ, Yegnasubramanian S, Palapattu GS, Rogers CG, Lin X, De Marzo AM, Nelson WG.
Molecular biomarker in prostate cancer: the role of CpG island hypermethylation.
Eur Urol. 2004;46(6):698-708.

Bastian PJ, Ellinger J, Schmidt D, Wernert N, Wellmann A, Muller SC, von Rucker A.
GSTP1 hypermethylation as a molecular marker in the diagnosis of prostatic cancer: is there acorrelation with clinical stage, Gleason grade, PSA value or age?
Eur J Med Res. 2004;9(11):523-7.

Li LC, Okino ST, Dahiya R.
DNA methylation in prostate cancer.
Biochim Biophys Acta. 2004;1704(2):87-102. Review .

Jeronimo C, Henrique R, Hoque MO, Ribeiro FR, Oliveira J, Fonseca D, Teixeira MR, Lopes C, Sidransky D.
Quantitative RARbeta2 hypermethylation: a promising prostate cancer marker.
Clin Cancer Res. 2004;10(12 Pt 1):4010-4.

Zhou M, Tokumaru, Y, Sidransky D, Epstein JI.
Quantitative GSTP1 methylation levels correlate with gleason grade and tumor volume in prostate needle biopsies.
J Urol 2004;171(6): 2195-8

Kang GH, Lee S, Lee HJ, Hwang KS.
Aberrant and hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia.
J Pathol 2004;202:233-40

Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, Bova GS, De Marzo AM, Isaccs WB, Nelson WG.
Hypermethylation of CpG islands in primary and metastatic human prostate cancer.
Cancer Res 2004;64(6):1975-86

Nakayama M, Gonzalgo ML, Yegnasubramanian S, LinX, De Marzo AM, Nelson WG.
GSTP1 CpG island hypermethylation as a molecular marker for prostate cancer.
J Cell Biochem 2004;91(3):540-52

Harden SV, Guo Z, Epstein JI, Sidransky D.
Quantitative GST-Pi methylation clearly distinguishes benign prostatic tissue and limited prostate carcinoma.
J. Urol. 2003;169:1138-42.

Jeronimo C, Usadel H, Henrique R, Oliveira J, Lopes C, Nelson W, Sidransky D.
Quantitation of GST-Pi methylation in non-neoplastic prostatic tissue and organ-confined prostate carcinoma.
J Nat Cancer Inst 2001;93(22):1747-52.

Lee W, Morton RA, Epstein JI, Brooks JD, Campbell PA, Bova GS, Hsieh W, Isaacs WB, Nelson WG.
Cytidine methylation of regulatory sequences near the p-class glutathione S-transferase gene accompanies human prostatic carcinogenesis.
PNAS, USA 1994;91:1733-7.